Clinigen has appointed Paul Carter as Non-Executive Chair of its Board
Clinigen, the global pharmaceutical services Group, has appointed seasoned biopharma executive Paul Carter as Non-Executive Chair of its Board.
This move strengthens the Board as Clinigen advances its strategic transformation and expands its role across the full pharmaceutical life cycle.
Paul brings nearly 30 years of global biopharma leadership experience, having held senior roles at Gilead Sciences, GlaxoSmithKline and SmithKline Beecham. At Gilead, he oversaw global commercial operations and $30 billion in annual revenue.
His experience spans North America, Europe and Asia, with a strong track record in commercial strategy and leadership.
In addition to his executive roles, Paul holds numerous board and advisory positions. He is currently Chair of Memo Therapeutics AG and Kyowa Kirin International PLC, and Board Director at Immatics NV. He also advises several healthcare investors and life sciences companies, and mentors executives via GLG Institute and Pioneering Collective.
Paul’s appointment comes at a pivotal time for Clinigen. His experience in launching market-leading products, scaling global operations and forming strategic partnerships will support the company’s goal of becoming the world’s premier end-to-end pharmaceutical life cycle partner.
Jerome Charton, CEO at Clinigen, commented: “Paul Carter’s appointment as Chair represents a significant milestone for Clinigen as we continue our strategic transformation. His visionary leadership and unparalleled commercial experience will be instrumental in executing our ambitious growth strategy.”
